RXRX - Recursion Pharmaceuticals, Inc.
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) fell 4.3% during trading on Tuesday. The company traded as low as $4.74 and last traded at $4.5750. Approximately 14,149,966 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 18,554,494 shares. The stock had previously closed at $4.78.
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 12.7% of Oramed Pharmaceuticals
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co.
Recursion Pharmaceuticals (NASDAQ: RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley's Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company's shift toward an end-to-end, AI-enabled drug discovery and development platform. Khan said the company has changed materially over the past 12 to 18 months, expanding its platform beyond biology
Recursion Pharmaceuticals NASDAQ: RXRX outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley's Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company's shift toward an end-to-end, AI-enabled drug discovery and development platform.
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Don't catch a falling knife.
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry's data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day.
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Recursion Pharmaceuticals (NASDAQ: RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference. Taylor described AI not as a "magic wand,"
Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.
California State Teachers Retirement System lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 64.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 574,637 shares of the company's stock after buying an additional 224,332 shares during the period.